vs

Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

SAUL CENTERS, INC. is the larger business by last-quarter revenue ($75.1M vs $44.6M, roughly 1.7× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). SAUL CENTERS, INC. runs the higher net margin — 8.7% vs -90.4%, a 99.1% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 10.6%). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 6.2%).

Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

BFS vs PACB — Head-to-Head

Bigger by revenue
BFS
BFS
1.7× larger
BFS
$75.1M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+3.2% gap
PACB
13.8%
10.6%
BFS
Higher net margin
BFS
BFS
99.1% more per $
BFS
8.7%
-90.4%
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
6.2%
BFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BFS
BFS
PACB
PACB
Revenue
$75.1M
$44.6M
Net Profit
$6.5M
$-40.4M
Gross Margin
37.1%
Operating Margin
65.4%
-92.3%
Net Margin
8.7%
-90.4%
Revenue YoY
10.6%
13.8%
Net Profit YoY
-19.6%
-1802.7%
EPS (diluted)
$0.15
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFS
BFS
PACB
PACB
Q4 25
$75.1M
$44.6M
Q3 25
$72.0M
$38.4M
Q2 25
$70.8M
$39.8M
Q1 25
$71.9M
$37.2M
Q4 24
$67.9M
$39.2M
Q3 24
$67.3M
$40.0M
Q2 24
$66.9M
$36.0M
Q1 24
$66.7M
$38.8M
Net Profit
BFS
BFS
PACB
PACB
Q4 25
$6.5M
$-40.4M
Q3 25
$10.5M
$-38.0M
Q2 25
$10.7M
$-41.9M
Q1 25
$9.8M
$-426.1M
Q4 24
$8.1M
$2.4M
Q3 24
$14.5M
$-60.7M
Q2 24
$14.4M
$-173.3M
Q1 24
$13.6M
$-78.2M
Gross Margin
BFS
BFS
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
73.6%
25.0%
Q2 24
74.2%
16.5%
Q1 24
72.8%
29.1%
Operating Margin
BFS
BFS
PACB
PACB
Q4 25
65.4%
-92.3%
Q3 25
69.1%
-101.1%
Q2 25
68.7%
-112.8%
Q1 25
66.5%
-1154.5%
Q4 24
82.9%
-390.1%
Q3 24
72.8%
-160.3%
Q2 24
75.0%
-488.3%
Q1 24
72.4%
-209.6%
Net Margin
BFS
BFS
PACB
PACB
Q4 25
8.7%
-90.4%
Q3 25
14.6%
-98.9%
Q2 25
15.1%
-105.4%
Q1 25
13.6%
-1146.8%
Q4 24
11.9%
6.0%
Q3 24
21.5%
-151.9%
Q2 24
21.6%
-481.3%
Q1 24
20.4%
-201.4%
EPS (diluted)
BFS
BFS
PACB
PACB
Q4 25
$0.15
$-0.11
Q3 25
$0.32
$-0.13
Q2 25
$0.33
$-0.14
Q1 25
$0.29
$-1.44
Q4 24
$0.22
$-0.44
Q3 24
$0.48
$-0.22
Q2 24
$0.48
$-0.64
Q1 24
$0.45
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFS
BFS
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$8.7M
$279.5M
Total DebtLower is stronger
$468.4M
Stockholders' EquityBook value
$307.8M
$5.3M
Total Assets
$2.2B
$784.1M
Debt / EquityLower = less leverage
1.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFS
BFS
PACB
PACB
Q4 25
$8.7M
$279.5M
Q3 25
$11.8M
$298.7M
Q2 25
$5.3M
$314.7M
Q1 25
$6.5M
$343.1M
Q4 24
$10.3M
$389.9M
Q3 24
$7.2M
$471.1M
Q2 24
$6.9M
$509.8M
Q1 24
$7.1M
$561.9M
Total Debt
BFS
BFS
PACB
PACB
Q4 25
$468.4M
Q3 25
$1.6B
Q2 25
$1.6B
Q1 25
$1.5B
Q4 24
$455.8M
Q3 24
$1.5B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
BFS
BFS
PACB
PACB
Q4 25
$307.8M
$5.3M
Q3 25
$316.6M
$36.1M
Q2 25
$322.4M
$61.5M
Q1 25
$328.4M
$91.6M
Q4 24
$335.8M
$506.6M
Q3 24
$341.8M
$453.1M
Q2 24
$345.7M
$492.7M
Q1 24
$347.1M
$649.0M
Total Assets
BFS
BFS
PACB
PACB
Q4 25
$2.2B
$784.1M
Q3 25
$2.2B
$803.2M
Q2 25
$2.1B
$825.5M
Q1 25
$2.1B
$860.8M
Q4 24
$2.1B
$1.3B
Q3 24
$2.1B
$1.5B
Q2 24
$2.1B
$1.5B
Q1 24
$2.0B
$1.7B
Debt / Equity
BFS
BFS
PACB
PACB
Q4 25
1.52×
Q3 25
5.02×
Q2 25
4.85×
Q1 25
4.70×
Q4 24
1.36×
Q3 24
4.37×
Q2 24
4.17×
Q1 24
4.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFS
BFS
PACB
PACB
Operating Cash FlowLast quarter
$99.8M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
15.35×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFS
BFS
PACB
PACB
Q4 25
$99.8M
$-19.1M
Q3 25
$20.6M
$-18.7M
Q2 25
$26.6M
$-29.4M
Q1 25
$30.4M
$-44.1M
Q4 24
$121.2M
$-30.6M
Q3 24
$26.5M
$-45.5M
Q2 24
$32.1M
$-54.3M
Q1 24
$33.8M
$-75.7M
Free Cash Flow
BFS
BFS
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-28.3M
$-46.3M
Q2 24
$-12.5M
$-55.7M
Q1 24
$-11.7M
$-79.6M
FCF Margin
BFS
BFS
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-42.1%
-115.7%
Q2 24
-18.7%
-154.8%
Q1 24
-17.6%
-205.0%
Capex Intensity
BFS
BFS
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
81.5%
2.0%
Q2 24
66.7%
4.1%
Q1 24
68.3%
10.0%
Cash Conversion
BFS
BFS
PACB
PACB
Q4 25
15.35×
Q3 25
1.97×
Q2 25
2.48×
Q1 25
3.10×
Q4 24
14.98×
-12.93×
Q3 24
1.83×
Q2 24
2.22×
Q1 24
2.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BFS
BFS

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons